HRP20190289T1 - Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba - Google Patents

Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba

Info

Publication number
HRP20190289T1
HRP20190289T1 HRP20190289TT HRP20190289T HRP20190289T1 HR P20190289 T1 HRP20190289 T1 HR P20190289T1 HR P20190289T T HRP20190289T T HR P20190289TT HR P20190289 T HRP20190289 T HR P20190289T HR P20190289 T1 HRP20190289 T1 HR P20190289T1
Authority
HR
Croatia
Prior art keywords
stemic
antigenes
prostate
stations
specific
Prior art date
Application number
HRP20190289TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Bachmann
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of HRP20190289T1 publication Critical patent/HRP20190289T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HRP20190289TT 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba HRP20190289T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (1)

Publication Number Publication Date
HRP20190289T1 true HRP20190289T1 (hr) 2019-05-03

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190289TT HRP20190289T1 (hr) 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba

Country Status (18)

Country Link
US (1) US9200078B2 (cg-RX-API-DMAC7.html)
EP (2) EP2726507B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014528696A (cg-RX-API-DMAC7.html)
AU (1) AU2012277784B2 (cg-RX-API-DMAC7.html)
CY (1) CY1121249T1 (cg-RX-API-DMAC7.html)
DE (1) DE102011118022B4 (cg-RX-API-DMAC7.html)
DK (1) DK2726507T3 (cg-RX-API-DMAC7.html)
ES (2) ES2711978T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190289T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042008T2 (cg-RX-API-DMAC7.html)
LT (1) LT2726507T (cg-RX-API-DMAC7.html)
PL (1) PL2726507T3 (cg-RX-API-DMAC7.html)
PT (1) PT2726507T (cg-RX-API-DMAC7.html)
RS (1) RS58448B1 (cg-RX-API-DMAC7.html)
SI (1) SI2726507T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900085T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901991T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013001065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN116406381A (zh) * 2020-05-19 2023-07-07 希望之城 工程化抗前列腺干细胞抗原融合蛋白及其用途
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
NZ337413A (en) * 1997-03-10 2003-02-28 Univ California Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
EP1753871B1 (en) * 2004-05-28 2015-07-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
EP2726507B1 (de) 2018-11-21
EP3505536B1 (de) 2024-08-07
TR201901991T4 (tr) 2019-03-21
JP2019193652A (ja) 2019-11-07
AU2012277784A1 (en) 2014-02-06
US20140134155A1 (en) 2014-05-15
DK2726507T3 (en) 2019-03-11
JP6549622B2 (ja) 2019-07-24
JP6886491B2 (ja) 2021-06-16
PT2726507T (pt) 2019-02-26
DE102011118022A1 (de) 2013-01-03
JP2021121201A (ja) 2021-08-26
ES2989975T3 (es) 2024-11-28
JP2014528696A (ja) 2014-10-30
ES2711978T3 (es) 2019-05-08
US9200078B2 (en) 2015-12-01
JP2017104113A (ja) 2017-06-15
DE102011118022B4 (de) 2018-01-18
HUE042008T2 (hu) 2019-06-28
EP3505536C0 (de) 2024-08-07
RS58448B1 (sr) 2019-04-30
JP7341185B2 (ja) 2023-09-08
SMT201900085T1 (it) 2019-05-10
EP3505536A1 (de) 2019-07-03
CY1121249T1 (el) 2020-05-29
LT2726507T (lt) 2019-04-10
EP2726507A1 (de) 2014-05-07
WO2013001065A1 (de) 2013-01-03
AU2012277784B2 (en) 2015-08-20
PL2726507T3 (pl) 2019-06-28
SI2726507T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
HRP20190289T1 (hr) Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba
SI2683406T1 (sl) Protitelesa ANTI-CD40 in njihova uporaba
IL231777B (en) Antibodies against tl1a and uses thereof
HRP20181515T1 (hr) Mezenhimne stromalne stanice i upotreba povezana s njima
IL231282A0 (en) Antibodies to 9pcsk and their uses
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
SI2970456T1 (sl) Postopki in sestavki za dostavo MRNA-kodiranih protiteles
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
SI2812443T1 (sl) Protitelesa CD47 in postopki za njihovo uporabo
ME03440B (me) Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
HRP20170713T1 (hr) Bispecifično anti-igf-1r i anti-erbb3 antitijelo
PL2731677T3 (pl) Przeciwciała wiążące się z OX40 i ich zastosowania
PL2888284T3 (pl) Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
EP2761554A4 (en) PAYMENTS IN SOCIAL PROXIMITY
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
PT3462173T (pt) Anticorpos contra risperidona e utilização dos mesmos
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
BR112014013034A2 (pt) método para produzir um anticorpo
PL2887952T3 (pl) Przeciwciała przeciwko haptenom olanzapinowym i ich zastosowanie
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112014008691A2 (pt) anticorpos para cd1d
FI20116306L (fi) Teroitin
HUE037212T2 (hu) Anti-alfa-V integrin ellenanyag prosztatarák kezelésére